A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a ...

Roche Holding (SWX:ROG) reported significant weight loss results from Phase II trials of its dual GLP-1/GIP obesity candidate ...

Roche has waved goodbye to an inflammation drug from Kiniksa Pharmaceuticals—as well as the $100 million that the pharma paid for the therapy—as part of a ...

BERLIN, Jan 27 (Reuters) - Roche's experimental obesity drug, which works in a similar way to Eli Lilly's Zepbound, produced ...

The Swiss drugmaker expects sales and core earnings per share to grow at constant currencies this year, partly due to the strength of its drug pipeline.

Roche’s dual GLP-1/GIP receptor agonist has been tied to 22.5% weight loss at 48 weeks, validating the company’s decision to move the asset into phase 3 studies this quarter.

Roche’s CT-388 phase 2 obesity results show 22.5% weight loss and solid tolerability vs tirzepatide—plus what’s next for ...

Roche’s Genentech plans to start its Phase 3 this quarter, but primary completion will happen by 2028. Click here to find out ...

Roche aims to become a “top three player” in obesity, Teresa Graham, CEO of the group’s Pharma unit, said Thursday during a ...

GENEVA (AP) — Swiss pharmaceuticals powerhouse Roche announced Tuesday it plans to invest $50 billion in the United States over the next five years, creating 12,000 jobs. The Basel-based company, ...

But a new antibiotic from Swiss pharmaceutical company Roche could change the future of how we treat Gram-negative bacteria. Roche announced on Monday that its antibiotic zosurabalpin will enter phase ...